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RE: MassHealth Drug List
 
 
Audience This bulletin contains important information about pharmacy services for 
MassHealth members.  This information is important for prescribers, 
pharmacies, community health centers, outpatient hospitals, and nursing 
facilities.  This information does not apply directly to other providers, 
including inpatient hospitals, but it is given for your information. 
 
 
MassHealth  Effective for prescriptions written on or after August 1, 2002, the Division  
Drug List  will begin using a new communication tool, the MassHealth Drug List, to 
specify which drugs need prior authorization when prescribed for 
MassHealth members.   
 
The MassHealth Drug List is an alphabetical list of commonly prescribed 
drugs.  Certain drugs have been grouped into their therapeutic classes.  
The MassHealth Drug List provides cross-references to their respective 
therapeutic class tables, which provide additional clinical information. The 
prior-authorization requirements specified in the MassHealth Drug List 
reflect the Division’s prior-authorization policy generally described in the 
pharmacy regulations and previous provider bulletins, as well as the 
Division’s and the Drug Utilization Review (DUR) Board’s review of 
certain gastrointestinal drugs.  The list also specifies the generic over-the-
counter drugs that are payable under MassHealth. Any drug that does not 
appear on the list also requires prior authorization. 
 
The Division and the DUR Board determined whether or not to require 
prior authorization on the basis of the drugs’ safety and effectiveness.  
Cost was a consideration only if two or more drugs were considered to be 
equally safe and effective.  In that case, the more expensive drug or 
drugs require prior authorization.   
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Drug List on The Division will update the MassHealth Drug List monthly, as needed,
the DMA and will post the updated list on its Web site on the first business day of
Web Site each month prior to the effective date of the change. The Division will
not send a bulletin each month in which there are changes to the list.
However, the Division will provide a summary page on the Web site when
the list is updated, and will send e-mail alerts to those who sign up for
them. (See page 6 of this bulletin for more information about e-mail
alerts.) To view, print, or download the most up-to-date version of the
Drug List, go to the Division’s Web site at:
www.mass.gov/dma
Pictured above is the home page of the Division’s Web site. Click the
word Pharmacy to get to the Pharmacy page, then click “MassHealth
Drug List.”
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Prior Prior-authorization requirements for specific drugs are indicated on the
Authorization MassHealth Drug List beside each listed drug that requires it. Brand-
for Drugs name drugs that have an FDA “A”-rated generic equivalent require prior
authorization and are identified by a number symbol (#) beside the name
of the drug. The generic versions of such drugs are payable under
MassHealth without prior authorization.
Note to pharmacists: Numerous products that you may dispense as
generics will appear as brand-name products on the MassHealth Drug
List. This is because the Division uses the “Orange Book” as the
source document for determining brand-generic equivalency.
Pharmacists can use the override codes in their pharmacy program
software to indicate that they are selecting a brand-name product as
their generic equivalent. In doing so, the pharmacy will be paid at the
generic rate.
Although the Division will not pay for drugs without prior authorization if
they require it, any remaining refills will be paid on an otherwise valid
prescription written before any new prior-authorization requirement for the
drug goes into effect.
Note to nursing facilities: Although doctors’ orders in a nursing
facility are usually reviewed every 30-60 days, prescriptions at the
pharmacy can be valid for up to a year. The pharmacist will know the
duration of the prescription.
Members with MassHealth is the payer of last resort. When the member’s primary
Other Health carrier has a preferred drug list, the prescriber must follow the rules of the
Insurance primary carrier first. The provider may bill the Division for the primary
insurer’s copayment without MassHealth prior authorization, except in
cases where the drug is subject to a pharmacy service limitation pursuant
to 130 CMR 406.413(B) through (E)(4) and (E)(6) through (E)(11). In
such cases, the prescriber must obtain MassHealth prior authorization in
order for the pharmacy to bill the Division for the copayment. These
service limitations are also described in various prescriber regulations at
130 CMR 433.443 (physician regulations); 130 CMR 420.418 (dental
regulations); 130 CMR 424.419 (podiatrist regulations); 130 CMR
410.463 (outpatient hospital regulations). These regulations are available
on the Division’s Web site.
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Members Enrolled MassHealth members enrolled in a MassHealth-contracted managed care
in Certain Health organization (currently Neighborhood Health Plan, BMC HealthNet Plan,
Plans Network Health, or Fallon Community Health Plan), who receive drug
benefits through their health plan, are subject to the rules of that health
plan.
New Prior In addition to the Division’s preexisting prior-authorization requirements
Authorization for drugs, the MassHealth Drug List contains new prior-authorization
Requirements requirements for certain gastrointestinal drugs. Any remaining refills will
Effective be paid on an otherwise valid prescription for one of these gastrointestinal
August 1, 2002 drugs that is written before August 1, 2002.
Please see the Gastrointestinal Drugs Therapeutic Class Table attached
to this bulletin. This table, in addition to other therapeutic class tables, is
part of the MassHealth Drug List, and is available on the Division’s Web
site.
The Division and the DUR Board have determined that, in general, agents
within each of these classes of gastrointestinal drugs are comparable in
safety and effectiveness, but not comparable in terms of cost.
H2 Antagonists
Effective for prescriptions written on or after August 1, 2002, Axid
(nizatadine), which does not have a generic equivalent, will require prior
authorization. Generic famotidine, ranitidine, and cimetidine will not
require prior authorization. Prescribers are encouraged to consider
switching their MassHealth patients who are taking Axid to a generic
H2 antagonist, if clinically appropriate.
Proton Pump Inhibitors (PPIs)
Effective for prescriptions written on or after August 1, 2002, all PPIs
except Protonix (and Prevacid and Prilosec with certain exceptions) will
require prior authorization. Prescribers are encouraged to consider
switching their MassHealth patients who are using PPIs to Protonix, if
clinically appropriate.
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Upcoming The Division and the DUR Board will continue to review new drugs
Therapeutic Class and additional classes of drugs in the coming months, and will
Prior Authorization post on the Division’s Web site a schedule of new prior-
Changes authorization requirements based on these reviews. The schedule will be
available on the Web site approximately one month before a new
requirement goes into effect. The following table shows some upcoming
changes to the MassHealth Drug List based on the Division’s and DUR
Board’s review of therapeutic classes.
Therapeutic Class
Posted on
Web
Effective
Date
Nonsteroidal anti-inflammatory Drugs 08/01/02 09/01/02
Antihistamines 09/03/02 10/01/02
Prior Authorization Effective August 1, 2002, the Division has three forms that may be used
Forms for requesting prior authorization for drugs. The forms are designed to
maximize the efficiency of the prior-authorization process by eliciting
pertinent information from the prescriber.
• To request prior authorization for a PPI, the prescriber should
complete and submit the Proton Pump Inhibitor Prior Authorization
Request form.
• To request prior authorization for a brand-name drug for which an
FDA “A”-rated generic is available, the prescriber should complete
and submit the Brand-Name Drug Prior Authorization Request
form.
• To request prior authorization for any other drug, the prescriber
should complete and submit the Drug Prior Authorization Request
form.
Providers can download the above prior-authorization forms from the
Division’s Web site, or may send a written request to the following
address or fax number for a supply of any of these forms.
MassHealth Forms Distribution
P.O. Box 9101
Somerville, MA 02145
Fax: 703-917-4937
When requesting forms from this address, providers must include their
provider number, street address (no post-office boxes), a contact name,
the exact name of the form (as indicated in bold above), and the quantity
desired.
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Prior Authorization The Division plans to develop more drug and drug-class specific prior-
Forms authorization forms over time to guide prescribers in providing the
(cont.) specific information needed for the DUR Program to review a request for
a specific drug. Prescribers should check the Web site frequently, or sign
up for e-mail alerts as described below, to receive notice of updates to the
MassHealth Drug List and the availability of new prior-authorization forms.
E-mail Alerts Since the MassHealth Drug List will change as often as monthly, you can
sign up for e-mail alerts that will inform you when the MassHealth Drug
List has been updated on the Web site. If there are changes to the list
from the previous month, they will be summarized on our Web site and
will also be integrated into the list upon the effective date. You will also
be able to print the Drug List from the Division’s Web site or save a copy
of it to your computer.
Requesting a You can get a paper copy of an updated list by submitting a request to:
Paper Copy of
the Drug List MassHealth Publications
P.O. Box 9101
Somerville, MA 02145
Fax: 617-576-4487
Include your MassHealth provider number, address, and a contact name
with your request. MassHealth Publications will send you the latest
version of the list. You will need to submit another written request each
time you want a paper copy.
Members may obtain a paper copy from the MassHealth Customer
Service Center at 1-800-841-2900 (TTY: 1-800-497-4648 for the deaf
and hard of hearing).
Questions or If you have questions or comments about the MassHealth Drug List, call
Comments the Drug Utilization Review Program at 1-800-745-7318, or send an
e-mail to masshealthdruglist@nt.dma.state.ma.us. The Division will
not answer e-mail inquiries directly, but will use these inquiries to
develop a frequently asked questions section about the MassHealth
Drug List for the Division’s Web site.
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Questions or When e-mailing a question or comment to the above e-mail address,
Comments please include your name, title, phone number, and fax number. This
(cont.) electronic mailbox should be used only for submitting questions or
comments about the MassHealth Drug List. You will receive an
automated response message that acknowledges receipt of your e-mail.
If you do not receive an automated reply, please resubmit your inquiry.
MassHealth If a member has any questions about the MassHealth Drug List,
Customer Service please refer the member to the MassHealth Customer Service Center
Center for at 1-800-841-2900 (TTY: 1-800-497-4648 for the deaf and hard of
Members hearing).
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Gastrointestinal Drugs – Histamine H2 Antagonists/ 
Proton Pump Inhibitors 
H2 Antagonists
Drug Name† PA Status Clinical Notes
Axid (nizatidine) PA
Pepcid # (famotidine *)
Tagamet # (cimetidine *)
Zantac # (ranitidine *)
Optimize dosing regimen:
• For duodenal or gastric ulcer treatment, administer total daily
dose between evening meal and bedtime – ulcer healing is
directly proportional to degree of nocturnal acid reduction
Duration of therapy:
• duodenal ulcer (DU) – 4 weeks
• gastric ulcer (GU) – 8 weeks
Proton Pump Inhibitors (PPIs)
Drug Name† PA Status Clinicial Notes
Aciphex (rabeprazole) PA
Nexium (esomeprazole) PA
Prevacid (lansoprazole) PA > 16 years
(except
suspension for
LTC members)
Prilosec (omeprazole) PA > 16 years
Protonix (pantoprazole)
Optimize dosing regimen:
• For maximum efficacy, a PPI must be taken in a fasting state,
just before or with breakfast. In general, for patients on PPIs it
is not necessary to prescribe other antisecretory agents (e.g.,
H2 antagonists, prostaglandins). If an antisecretory agent is
prescribed with a PPI, the PPI should not be taken within 6
hours of the H2 antagonist or prostaglandin. PPIs should not
be taken on an “as needed” basis.
QD dosing versus BID dosing:
• QD dosing is adequate for most individuals except for
H.pylori treatment (PPI is BID for 1st two weeks of therapy).
For pathological hypersecretory conditions, such as ZE
Syndrome, a BID PPI regimen may be needed for high total
daily doses. When/if a second dose is prescribed, it should be
given just before the evening meal.
Apparent PPI non-responder:
• Careful history should be obtained to ensure appropriate
timing of drug administration and no significant drug
interactions (see above), before prescribing a second dose or
switching to another PPI
Duration of therapy:
• duodenal ulcer (DU) – 4 weeks (QD dosing)
• gastric ulcer (GU) – 8 weeks (QD dosing)
• H. pylori – 2 weeks (BID dosing) + 2 more weeks if DU
using QD dosing and 6 more weeks if GU using QD dosing
• acute symptomatic GERD – 4-8 weeks (QD dosing)
† Brand-name products are capitalized. Generic products are in lowercase.
# Prior authorization is required for the brand. An FDA “A”-rated generic is available without prior authorization.
* The generic OTC and, if any, generic prescription versions of the drug are payable under MassHealth without prior
authorization.
